Elisa Martín-Merino1, Ana Ruigómez, Saga Johansson, Mari-Ann Wallander, Luis A García-Rodriguez. 1. Centro Español de Investigación Farmacoepidemiológica , Madrid, Spain ; AstraZeneca R&D, Mölndal, and Section of Preventive Cardiology, Gothenburg University, Sweden ; and Department of Public Health and Caring Science, Uppsala University, Sweden.
Abstract
OBJECTIVE: To estimate the prevalence and incidence of depression; investigate its association with risk factors including comorbidities and drug and health care use; and describe treatment patterns of depression in primary care using The Health Improvement Network database. METHOD: In this cohort study, subjects with a first recorded diagnosis of depression (Read code) between January 1, 2002, and December 31, 2004 (n=47,170) were identified from a source population of 1,287,829 subjects aged 10-79 years. A comparison group was sampled from the same population and frequency matched to the depression cohort by age, sex, and calendar year (n=50,000). Depression diagnoses were validated using physician-completed questionnaires. Odds ratios and 95% CIs for the relationship of depression with a range of factors were estimated using unconditional logistic regression in a nested case-control analysis. RESULTS: The prevalence of depression was 11.23% (95% CI, 11.18-11.28). This prevalence decreased with increasing age and was higher in women than in men. The incidence was 13.89 per 1,000 person-years (95% CI, 13.82-14.08). Depression was associated with frequent use of health services, smoking, pregnancy in the previous year, anxiety, stress, sleep disorders, digestive and respiratory disorders, and pain. In the trimester following diagnosis, 82% of cases were treated-98% with antidepressants and 81.5% with selective serotonin reuptake inhibitors (SSRIs). CONCLUSIONS: We found a high prevalence and incidence of depression diagnoses in primary care in the United Kingdom. Following diagnosis, the majority of individuals were prescribed SSRIs. A diagnosis of depression is associated with a number of prior comorbidities, which could mask the depression. This fact should be taken into account when screening individuals in primary care.
OBJECTIVE: To estimate the prevalence and incidence of depression; investigate its association with risk factors including comorbidities and drug and health care use; and describe treatment patterns of depression in primary care using The Health Improvement Network database. METHOD: In this cohort study, subjects with a first recorded diagnosis of depression (Read code) between January 1, 2002, and December 31, 2004 (n=47,170) were identified from a source population of 1,287,829 subjects aged 10-79 years. A comparison group was sampled from the same population and frequency matched to the depression cohort by age, sex, and calendar year (n=50,000). Depression diagnoses were validated using physician-completed questionnaires. Odds ratios and 95% CIs for the relationship of depression with a range of factors were estimated using unconditional logistic regression in a nested case-control analysis. RESULTS: The prevalence of depression was 11.23% (95% CI, 11.18-11.28). This prevalence decreased with increasing age and was higher in women than in men. The incidence was 13.89 per 1,000 person-years (95% CI, 13.82-14.08). Depression was associated with frequent use of health services, smoking, pregnancy in the previous year, anxiety, stress, sleep disorders, digestive and respiratory disorders, and pain. In the trimester following diagnosis, 82% of cases were treated-98% with antidepressants and 81.5% with selective serotonin reuptake inhibitors (SSRIs). CONCLUSIONS: We found a high prevalence and incidence of depression diagnoses in primary care in the United Kingdom. Following diagnosis, the majority of individuals were prescribed SSRIs. A diagnosis of depression is associated with a number of prior comorbidities, which could mask the depression. This fact should be taken into account when screening individuals in primary care.
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: Daniel Polsky; Jalpa A Doshi; Steven Marcus; David Oslin; Aileen Rothbard; Niku Thomas; Christy L Thompson Journal: Arch Intern Med Date: 2005-06-13
Authors: Michael King; Irwin Nazareth; Gus Levy; Carl Walker; Richard Morris; Scott Weich; Juan Angel Bellón-Saameño; Berta Moreno; Igor Svab; Danica Rotar; J Rifel; Heidi-Ingrid Maaroos; Anu Aluoja; Ruth Kalda; Jan Neeleman; Mirjam I Geerlings; Miguel Xavier; Manuel Caldas de Almeida; Bernardo Correa; Francisco Torres-Gonzalez Journal: Br J Psychiatry Date: 2008-05 Impact factor: 9.319
Authors: W M Wong; K C Lai; K F Lam; W M Hui; W H C Hu; C L K Lam; H H X Xia; J Q Huang; C K Chan; S K Lam; B C Y Wong Journal: Aliment Pharmacol Ther Date: 2003-09-15 Impact factor: 8.171
Authors: Ellen A Schur; Niloofar Afari; Helena Furberg; Megan Olarte; Jack Goldberg; Patrick F Sullivan; Dedra Buchwald Journal: J Gen Intern Med Date: 2007-06 Impact factor: 5.128
Authors: Daniele Furtado; Helena Hachul; Monica L Andersen; Rodrigo A Castro; Manoel B Girão; Sergio Tufik Journal: Int Urogynecol J Date: 2011-08-17 Impact factor: 2.894
Authors: Laura J White; Edie R Hapner; Adam M Klein; John M Delgaudio; John J Hanfelt; H A Jinnah; Michael M Johns Journal: J Voice Date: 2011-12-29 Impact factor: 2.009